Oxford-AstraZeneca
Nigeria records 63 new coronavirus cases
Nigeria on Friday recorded 63 new coronavirus infections in seven states and the Federal Capital Territory (FCT). The new figure raised the total number of infections in the country to 166,254, an update published by the Nigeria Centre for Disease Control (NCDC) Friday night indicates. According to the update, no new death was recorded from the virus, which has already claimed 2,071 lives in the country. The data shows that the new COVID-19 cases were reported in seven states and Abuja. Lagos recorded 25 cases, closely followed by Ondo with 22. Rivers State reported six while Akwa Ibom and Kaduna reported three each. Also, Kwara State reported two while Ebonyi and FCT reported one each. A breakdown of the data shows that 11 people were discharged on Friday after testing negative for the vi...
AstraZeneca: ‘No evidence’ of higher blood clots risk from coronavirus vaccine
UK-based pharmaceutical company AstraZeneca insisted on Friday its coronavirus vaccine was safe after some countries suspended its use in response to concerns about a potential link to blood clots. “An analysis of our safety data of more than 10 million records has shown no evidence of an increased risk of pulmonary embolism or deep vein thrombosis in any defined age group, gender, batch or in any particular country” from the jab, a company spokesperson said. “In fact, the observed number of these types of events are significantly lower in those vaccinated than would be expected among the general population.” The AstraZeneca jab, developed with Oxford University, forms the mainstay of Britain’s vaccination programme, and of many developing economies. It is relatively cheap and easier to st...
Coronavirus vaccine breakthrough raises hopes of rapid global rollout
A coronavirus vaccine developed by Britain’s University of Oxford and the pharmaceutical firm AstraZeneca has shown successful results in early trials. If it is approved by regulators, the vaccine appears suitable for a fast rollout around the globe. Early analysis of trials involving 20,000 volunteers in Britain and Brazil show the vaccine is at least 62% effective after two doses. In volunteers given a different dosing regimen — a half dose, followed by a full dose — that figure rose to 90%. The average efficacy of the two dosing methods is 70%. None of those given the vaccine developed severe COVID-19 illness. Andrew Pollard, director of the Oxford Vaccine Group, said the recent successful trials of three different vaccines by Oxford-AstraZeneca, Pfizer-BioNTech and Moderna, represent a...
